Redasemtide

Phase 2Peptide

Shionogi

Redasemtide is one of 28 biologic programs targeting Ischemic stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Repatha

Amgen

Preclinical

2 2

Levaquin

WWim Janssens

Preclinical

3 3

Tylenol

KKenvue Brands

Preclinical

1 4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Statins

Sanofi

Preclinical

1 7

Redasemtide

Shionogi

Phase 2

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Active, not recruiting· Shionogi logo

Shionogi·Phase 2·NCT05953480·680 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Redasemtide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Redasemtide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Redasemtide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shionogi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: Shionogi

Redasemtide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News